Study on the Effect of Chemo-Radiation on the Serum Levels of IGF-I in Patients with Cancer Cervix Stage IIIB

  • Priya Iyer
  • Venkatraman Radhakrishnan
  • Rakesh Vyas
  • Sunil Trivedi
Original Article



Insulin-like growth factor type 1 (IGF-1) plays an important role in cancer proliferation and drug resistance. There are no published data on serum IGF-1 levels and the effect of chemo-radiotherapy on IGF-1 levels in advanced cervical cancer.


The study was a prospective observational study conducted at a tertiary cancer center. It included patients diagnosed with stage IIIB cervical cancer. Patients were treated with chemo-radiotherapy. IGF-1 levels were measured at baseline, 1 month and 6 months after completion of treatment.


The study included 32 patients with a median age of 42 years. All patients completed the planned treatment. The mean IGF-1 levels at baseline, 1-month and 6-month post-treatment were 168.40 ng/ml, 197.1 ng/ml and 146.51 ng/ml, respectively. The IGF-1 levels increased with treatment (P = 0.13) and then declined on follow-up (P = 0.003). IGF-1 levels did not correlate with tumor size or response to treatment.


Serum IGF-1 levels in advanced cervical cancer increase with chemo-radiotherapy and decline on follow-up. Further studies are required to understand the implication of this finding.


Cervical cancer IGF Radiotherapy Chemotherapy 


Compliance with Ethical Standards


The study was funded by Gujarat Cancer Research Institute.

Conflict of interest

None of the authors have any conflict of interest.

Ethical Approval

All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed Consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Maheshwari A, Kumar N, Mahantshetty U. Gynecological cancers: a summary of published Indian data. South Asian J Cancer. 2016;5:112–20.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Weroha SJ, Haluska P. The insulin-like growth factor system in cancer. Endocrinol Metab Clin North Am. 2012;41:335–50.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Denduluri SK, Idowu O, Wang Z, Liao Z, Yan Z, Mohammed MK, Ye J, Wei Q, Wang J, Zhao L, Luu HH. Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes Dis. 2015;2:13–25.CrossRefPubMedGoogle Scholar
  4. 4.
  5. 5.
    Mathur SP, Mathur RS, Underwood PB, Kohler MF, Creasman WT. Circulating levels of insulin-like growth factor-II and IGF-binding protein 3 in cervical cancer. Gynecol Oncol. 2003;91:486–93.CrossRefPubMedGoogle Scholar
  6. 6.
    Lloret M, Lara PC, Bordón E, Pinar B, Rey A, Falcón O, Molano F. Hernández MA IGF-1R expression in localized cervical carcinoma patients treated by radiochemotherapy. Gynecol Oncol. 2007;106:8–11.CrossRefPubMedGoogle Scholar
  7. 7.
    Serrano ML, Romero A, Cendales R, Sánchez-Gómez M, Bravo MM. Serum levels of insulin-like growth factor-1 and -2 and insulin like growth factor binding protein 3 in women with squamous intraepithelial lesions and cervical cancer. Biomedica. 2006;26(2):258–68.CrossRefPubMedGoogle Scholar
  8. 8.
    Huang YF, Shen MR, Hsu KF, Cheng YM, Chou CY. Clinical implications of insulin-like growth factor 1 system in early stage cervical cancer. Br J Cancer. 2008;99:1096–102.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Chanson P, Arnoux A, Mavromati M, Brailly-Tabard S, Massart C, Young J, Piketty ML, Souberbielle JC. VARIETE investigators. Reference values for IGF-I serum concentrations: comparison of six immunoassays. J Clin Endocrinol Metab. 2016;101:3450–8.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363:1346–53.CrossRefPubMedGoogle Scholar
  11. 11.
    Svensson J, Carlzon D, Petzold M, Karlsson MK, Ljunggren Ö, Tivesten A, Mellström D, Ohlsson C. Both low and high serum IGF-I levels associate with cancer mortality in older men. J Clin Endocrinol Metab. 2012;97:4623–30.CrossRefPubMedGoogle Scholar
  12. 12.
    Cao Y, Nimptsch K, Shui IM, Platz EA, Wu K, Pollak MN, Kenfield SA, Stampfer MJ, Giovannucci EL. Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer. Int J Cancer. 2015;136:2418–26.CrossRefPubMedGoogle Scholar
  13. 13.
    Durzyńska J. IGF axis and other factors in HPV-related and HPV-unrelated carcinogenesis (review). Oncol Rep. 2014;32:2295–306.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Heidegger I, Massoner P, Sampson N, Klocker H. The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer. Cancer Lett. 2015;367:113–21.CrossRefPubMedGoogle Scholar

Copyright information

© Association of Gynecologic Oncologists of India 2017

Authors and Affiliations

  • Priya Iyer
    • 1
  • Venkatraman Radhakrishnan
    • 2
  • Rakesh Vyas
    • 3
  • Sunil Trivedi
    • 4
  1. 1.Department of RadiotherapyCancer Institute (WIA)AdyarIndia
  2. 2.Department of Medical OncologyCancer Institute (WIA)AdyarIndia
  3. 3.Department of RadiotherapyGCRIAhmedabadIndia
  4. 4.Receptor Growth Factor LaboratoryGCRIAhmedabadIndia

Personalised recommendations